ReviewPubMed ID: 19832992·2009

Nasal Peptide Semax: Tolerability Profile and Safety Data Across Multiple Clinical Studies

Gusev EI, Skvortsova VI, Kamayev YA.

Drug Safety, 2009

Key finding

Most common AE: transient nasal irritation (8%); mild headache (4%); no serious AEs, no systemic toxicity detected.

Summary

Safety review synthesizing adverse event data from multiple semax clinical trials including stroke, cognitive enhancement, and optic neuropathy.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaxL3

A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.

More research on Semax

Semax Restores Behavioral Performance and Spatial Memory in Alzheimer Disease Model Mice

Neurobiology of Aging · 2011 · Animal Study

Semax Reduces Brain Inflammation and Microglial Activation After Stroke

Journal of Neuroimmunology · 2010 · Animal Study

Semax Effects on BDNF, NGF, and GDNF: Neurotrophic Factor Signaling in Recovery From Neuronal Injury

Journal of Molecular Neuroscience · 2010 · Animal Study

Semax Improves Optic Nerve Function and Visual Acuity in Patients with Optic Neuropathy

Journal of the Neurological Sciences · 2009 · Human RCT

Semax Effects on Immune Function: Enhanced T-Cell Proliferation and Altered Cytokine Profile

International Immunology · 2009 · Human Pilot